neoadjuvant
53 articles
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Two New Immunotherapy Trials Aim to Make Therapy More Effective
Two clinical trials in the Lustgarten Foundation’s Clinical Accelerator are testing different combinations of immunotherapy.
Using Molecular Tumor Profiling to Determine the Best Pancreatic Cancer Treatment
A clinical trial looks at whether molecular subtyping of tumors is effective in determining the best pancreatic cancer treatment.
Large Phase III Global Trial Targets Cancer Metabolism
Dr. Philip Philip focuses on disrupting cancer cell metabolism with devimistat, now in a phase III global clinical trial.
Overcoming Challenges to Vaccine Immunotherapy
Dr. Elizabeth Jaffee explains the challenges facing the scientists developing vaccine-based immunotherapy for pancreatic cancer.
Exercise Helps Boost Immune System and Immunotherapy Treatment
Dr. Emma Kurz is part of a research team that has found that exercise can help make immunotherapy more effective for pancreatic cancer.
For Pancreatic Cancer Patients, Pain Control Through Targeted Radiotherapy
Dr. Yaacov Lawrence is using celiac plexus radiotherapy in a clinical trials to target a source of pain for pancreatic cancer patients.
